Summary of Schrödinger's 2026 Conference Call Company Overview - **Company**: Schrödinger (NasdaqGS:SDGR) - **Industry**: Healthcare, specifically in drug discovery and computational chemistry Key Points and Arguments Transition to Annual Contract Value (ACV) - Schrödinger is transitioning to an ACV model to provide better revenue visibility and align with customer demands, which is expected to grow by 10%-15% annually [18][17] - The shift to hosted contracts will result in a decline in revenue for 2026 due to the recognition of revenue being ratable over the contract's life, contrasting with the previous model where revenue was recognized mostly in the quarter booked [18][19] - The company anticipates that this transition will stabilize over a three-year period as more contracts shift to the hosted model [19] Investor Concerns - There is investor skepticism regarding whether the shift to ACV is a way to mask declining new contract ACVs. However, management clarified that ACV growth reflects true business growth and customer adoption [28][36] - The company emphasized that if ACV is not growing, the business is not growing, and thus there is no intention to obscure financial performance [36][28] Collaboration and Partnerships - Schrödinger has a strong track record of successful collaborations, having generated $650 million from equity stakes, milestones, and upfront payments over the last five years [49] - The company has 16 programs in clinical trials that generate royalties, showcasing the effectiveness of its platform in drug discovery [50] AI and Technology Disruption - Management addressed concerns about AI potentially disrupting their business, asserting that AI cannot replace the foundational physics required for drug discovery [72][70] - The proprietary knowledge and technology developed by Schrödinger are deemed irreplaceable, and the company is not worried about AI competition in their specific domain [72][73] Predictive Toxicology Module - The predictive toxicology module is expected to be a significant growth driver, addressing a major source of failure in drug discovery [84] - Customers will pay extra for this new module, tapping into larger budgets from toxicology groups rather than just research groups [85] - The company anticipates that this module will contribute to growth over the coming years, with positive feedback from beta testing [99][98] Market Dynamics and Growth Opportunities - While the company is not relying on a re-acceleration of the IPO market for immediate growth, they expect biotech and life sciences markets to return to historical levels over the next three years [105] - Schrödinger is also exploring growth opportunities in materials science, leveraging their existing technologies to address challenges in that field [112][114] Long-term Vision and Capital Use - The company aims to continue innovating in drug discovery and materials science, with a focus on reducing the time and cost associated with bringing new drugs to market [146] - As profitability is achieved, Schrödinger plans to increase its ownership stake in co-founded companies, which could enhance shareholder value [148][149] Conclusion - Schrödinger is positioned for growth through its transition to ACV, successful collaborations, and innovative technologies in drug discovery and materials science. The company remains focused on long-term innovation and profitability while addressing investor concerns transparently.